Chemotherapy, Cancer, Regional Perfusion: Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.Perfusion: Treatment process involving the injection of fluid into an organ or tissue.Nitrogen Radioisotopes: Unstable isotopes of nitrogen that decay or disintegrate emitting radiation. N atoms with atomic weights 12, 13, 16, 17, and 18 are radioactive nitrogen isotopes.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Ventilation-Perfusion Ratio: The ratio of alveolar ventilation to simultaneous alveolar capillary blood flow in any part of the lung. (Stedman, 25th ed)Coronary Circulation: The circulation of blood through the CORONARY VESSELS of the HEART.Pulmonary Circulation: The circulation of the BLOOD through the LUNGS.Microspheres: Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Tomography, Emission-Computed, Single-Photon: A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.Regional Blood Flow: The flow of BLOOD through or around an organ or region of the body.Tomography, Emission-Computed: Tomography using radioactive emissions from injected RADIONUCLIDES and computer ALGORITHMS to reconstruct an image.Perfusion Imaging: The creation and display of functional images showing where the blood flow reaches by following the distribution of tracers injected into the blood stream.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Cerebrovascular Circulation: The circulation of blood through the BLOOD VESSELS of the BRAIN.Positron-Emission Tomography: An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Hemodynamics: The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.Myocardial Perfusion Imaging: The creation and display of functional images showing where the blood is flowing into the MYOCARDIUM by following over time the distribution of tracers injected into the blood stream.Lung: Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.Breast Neoplasms: Tumors or cancer of the human BREAST.Heart: The hollow, muscular organ that maintains the circulation of the blood.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Lung Neoplasms: Tumors or cancer of the LUNG.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Early Detection of Cancer: Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Stomach Neoplasms: Tumors or cancer of the STOMACH.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Colonic Neoplasms: Tumors or cancer of the COLON.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Taxoids: A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).DeoxycytidineTime Factors: Elements of limited time intervals, contributing to particular results or situations.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Cell Line, Tumor: A cell line derived from cultured tumor cells.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Antineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Organoplatinum Compounds: Organic compounds which contain platinum as an integral part of the molecule.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Induction Chemotherapy: Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Liver Neoplasms: Tumors or cancer of the LIVER.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Anthracyclines: Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Testicular Neoplasms: Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Radiopharmaceuticals: Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Bleomycin: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Ifosfamide: Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Rectal Neoplasms: Tumors or cancer of the RECTUM.Medical Oncology: A subspecialty of internal medicine concerned with the study of neoplasms.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Reproducibility of Results: The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Antibodies, Monoclonal, Humanized: Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.Palliative Care: Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Risk: The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome.Peritoneal Neoplasms: Tumors or cancer of the PERITONEUM.Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Technetium Tc 99m Sestamibi: A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Quality of Life: A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Contrast Media: Substances used to allow enhanced visualization of tissues.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Genetic Predisposition to Disease: A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.Organotechnetium Compounds: Organic compounds that contain technetium as an integral part of the molecule. These compounds are often used as radionuclide imaging agents.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Antineoplastic Agents, Hormonal: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)United StatesNeoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Registries: The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Drug Screening Assays, Antitumor: Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.Recurrence: The return of a sign, symptom, or disease after a remission.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Hyperthermia, Induced: Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.Infusions, Intra-Arterial: Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.Receptors, Progesterone: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.Neoplasms, Germ Cell and Embryonal: Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.DNA, Neoplasm: DNA present in neoplastic tissue.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Granulocyte Colony-Stimulating Factor: A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Transplantation, Heterologous: Transplantation between animals of different species.Tegafur: Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.Neoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Odds Ratio: The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Mastectomy: Surgical procedure to remove one or both breasts.Dacarbazine: An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Pilot Projects: Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Mitoxantrone: An anthracenedione-derived antineoplastic agent.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)Molecular Targeted Therapy: Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Lomustine: An alkylating agent of value against both hematologic malignancies and solid tumors.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Drug Therapy: The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.Chemoradiotherapy: Treatment that combines chemotherapy with radiotherapy.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Antiemetics: Drugs used to prevent NAUSEA or VOMITING.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.SEER Program: A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)Microcirculation: The circulation of the BLOOD through the MICROVASCULAR NETWORK.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Clinical Trials, Phase III as Topic: Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Neoplasms, Hormone-Dependent: Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.DNA Methylation: Addition of methyl groups to DNA. DNA methyltransferases (DNA methylases) perform this reaction using S-ADENOSYLMETHIONINE as the methyl group donor.Models, Biological: Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Bridged Compounds: Cyclic hydrocarbons that contain multiple rings and share one or more atoms.Platinum Compounds: Inorganic compounds which contain platinum as the central atom.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Gastrointestinal Neoplasms: Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.Germinoma: A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)

L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer. (1/241)

PET with L-[1-11C]-tyrosine (TYR) was investigated in patients undergoing hyperthermic isolated limb perfusion (HILP) with recombinant tumor necrosis factor alpha (rTNF-alpha) and melphalan for locally advanced soft-tissue sarcoma and skin cancer of the lower limb. METHODS: Seventeen patients (5 women, 12 men; age range 24-75 y; mean age 52 y) were studied. TYR PET studies were performed before HILP and 2 and 8 wk afterwards. The protein synthesis rates (PSRs) in nanomoles per milliliter per minute were calculated. After final PET studies, tumors were resected and pathologically examined. Patients with pathologically complete responses (pCR) showed no viable tumors after treatment. Those with pathologically partial responses (pPR) showed various amounts of viable tumors in the resected tumor specimens. RESULTS: Six patients (35%) showed a pCR and 11 patients (65%) showed a pPR. All tumors were depicted as hot spots on PET studies before HILP. The PSR in the pCR group at 2 and 8 wk after perfusion had decreased significantly (P < 0.05) in comparison to the PSR before HILP. A significant difference was found in PSR between the pCR and pPR groups at 2 and at 8 wk (P < 0.05). Median PSR in nonviable tumor tissue was 0.62 and ranged from 0.22 to 0.91. With a threshold PSR of 0.91, sensitivity and specificity of TYR PET were 82% and 100%, respectively. The predictive value of a PSR > 0.91 for having viable tumor after HILP was 100%, whereas the predictive value of a PSR < or = 0.91 for having nonviable tumor tissue after HILP was 75%. The 2 patients in the pPR groups with a PSR < 0.91 showed microscopic islets of tumor cells surrounded by extensive necrosis on pathological examination. CONCLUSION: Based on the calculated PSR after HILP, TYR PET gave a good indication of the pathological outcome. Inflammatory tissue after treatment did not interfere with viable tumor on the images, suggesting that it may be worthwhile to pursue TYR PET in other therapy evaluation settings.  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (2/241)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Metabolism of [14C]phenol in the isolated perfused mouse liver. (3/241)

A previous report from this laboratory focused on the metabolism of [14C]benzene (BZ) in the isolated, perfused, mouse liver (C. C. Hedli, et al., 1997, Toxicol. Appl. Pharmacol. 146, 60-68). Whereas administration of BZ to mice results in bone marrow depression (R. Snyder et al., 1993, Res. Commun. Chem. Pathol. Pharmacol. 20, 191-194), administration of phenol (P), the major metabolite of BZ, does not. It was, therefore, of interest to determine whether the metabolic fate of P produced during BZ metabolism differed from that of P metabolized in the absence of BZ. Mouse livers were perfused with a solution of [14C]P in both the orthograde (portal vein to central vein) and retrograde (central vein to portal vein) direction to investigate the metabolic zonation of enzymes involved in P hydroxylation and conjugation. Perfusate samples were collected, separated by HPLC, and tested for radioactivity. Unconjugated metabolites were identified by comparing their retention times with nonradiolabeled standards, which were detected by UV absorption. Conjugated metabolites were identified and collected on the basis of radiochromatogram results, hydrolyzed enzymatically, and identified by co-chromatography with unlabeled BZ metabolites. The objective was to compare and quantify the metabolites formed during the perfusion of P in the orthograde and retrograde directions and to compare the orthograde P-perfusion results with the orthograde BZ results reported previously. Regardless of the direction of P perfusion, the major compounds released from the liver were P. phenylgucuronide, phenylsulfate, hydroquinone (HQ), and HQ glucuronide. A comparison of the results of perfusing P in the orthograde versus the retrograde direction showed that more P was recovered unchanged and more HQ was formed during retrograde perfusion. The results suggest that enzymes involved in P hydroxylation are generally closer to the central vein than those involved in conjugation, and that during retrograde perfusion, P metabolism may be limited by the sub-optimal conditions of perfusion. Comparison of the orthograde perfusion studies of P and BZ revealed that a larger percentage of the radioactivity released from the liver was identified as unconjugated HQ after BZ perfusion than after P perfusion. In addition, the amount of radioactivity covalently bound to liver macromolecules was measured after each perfusion and determined to be proportional to the amount of HQ and HQG detected in the perfusate samples.  (+info)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. (4/241)

An isolated limb perfusion (ILP) model using soft tissue sarcoma-bearing rats was used to study prerequisites for an effective ILP, such as oxygenation of the perfusate, temperature of the limb, duration of the perfusion and concentration of tumour necrosis factor (TNF). Combination of 50 microg TNF and 40 microg melphalan demonstrated synergistic activity leading to a partial and complete response rate of 71%. In comparison to oxygenated ILP, hypoxia was shown to enhance anti-tumour activity of melphalan alone and TNF alone but not of their combined use. Shorter perfusion times decreased anti-tumour responses. At a temperature of 24-26 degrees C, anti-tumour effects were lost, whereas temperatures of 38-39 degrees C or 42-43 degrees C resulted in higher response rates. However, at 42-43 degrees C, local toxicity impaired limb function dramatically. Synergy between TNF and melphalan was lost at a dose of TNF below 10 microg in 5 ml perfusate. We conclude that the combination of TNF and melphalan has strong synergistic anti-tumour effects in our model, just as in the clinical setting. Hypoxia enhanced activity of melphalan and TNF alone but not the efficacy of their combined use. For an optimal ILP, minimal perfusion time of 30 min and minimal temperature of 38 degrees C was mandatory. Moreover, the dose of TNF could be lowered to 10 microg per 5 ml perfusate, which might allow the use of TNF in less leakage-free or less inert perfusion settings.  (+info)

Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. (5/241)

Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan (HILP-TM) with or without IFN-gamma is a promising local treatment in patients with locally advanced extremity soft tissue sarcomas (STSs), with response rates of up to 84%. The mechanisms of the treatment response are poorly understood. Here, we determined the HILP-TM-induced changes in mitotic activity, proliferation, and apoptosis in 37 STSs; the additional effect of IFN-gamma; and the association of HILP-TM with treatment response and clinical outcome. On archival material, obtained before and 6-8 weeks after HILP-TM with (n = 15) or without (n = 22) IFN-gamma, the number of mitoses was counted, and the proliferation fraction was determined by immunohistological staining for the proliferation associated Ki-67 antigen (MIB1). Apoptosis was visualized by enzymatic detection of DNA fragmentation (terminal deoxynucleotidyl transferase-mediated nick end labeling method). Clinical and histological response, follow-up status, and survival were recorded. The number of mitoses dropped 57% and proliferation rate decreased with 40% after HILP-TM, whereas the amount of apoptosis after HILP-TM more than doubled as before HILP-TM. The addition of IFN-gamma to HILP-TM did not influence the changes in tumor parameters and did not affect treatment response. A better clinical response to HILP-TM was correlated with high mitotic activity and low amount of apoptosis in tumor samples before HILP-TM. Patients with highly proliferative STS before and after HILP-TM had a relatively poor prognosis. Furthermore, patients who developed distant metastases after HILP-TM had a relatively high number of dividing cells in the tumor remnants after treatment.  (+info)

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. (6/241)

We have shown previously that isolated limb perfusion (ILP) in sarcoma-bearing rats results in high response rates when melphalan is used in combination with tumour necrosis factor alpha (TNF-alpha). This is in line with observations in patients. Here we show that ILP with doxorubicin in combination with TNF-alpha has comparable effects in two different rat sarcoma tumour models. The addition of TNF-alpha exhibits a synergistic anti-tumour effect, resulting in regression of the tumour in 54% and 100% of the cases for the BN175-fibrosarcoma and the ROS-1 osteosarcoma respectively. The combination is shown to be mandatory for optimal tumour response. The effect of high dose TNF-alpha on the activity of cytotoxic agents in ILP is still unclear. We investigated possible modes by which TNF-alpha could modulate the activity of doxorubicin. In both tumour models increased accumulation of doxorubicin in tumour tissue was found: 3.1-fold in the BN175 and 1.8-fold in the ROS-1 sarcoma after ILP with doxorubicin combined with TNF-alpha in comparison with an ILP with doxorubicin alone. This increase in local drug concentration may explain the synergistic anti-tumour responses after ILP with the combination. In vitro TNF-alpha fails to augment drug uptake in tumour cells or to increase cytotoxicity of the drug. These findings make it unlikely that TNF-alpha directly modulates the activity of doxorubicin in vivo. As TNF-alpha by itself has no or only minimal effect on tumour growth, an increase in local concentrations of chemotherapeutic drugs might well be the main mechanism for the synergistic anti-tumour effects.  (+info)

Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. (7/241)

A phase I dose-escalation study was performed to determine whether isolated hepatic perfusion (IHP) with melphalan (L-PAM) allows exposure of the liver to much higher drug concentrations than clinically achievable after systemic administration and leads to higher tumour concentrations of L-PAM. Twenty-four patients with colorectal cancer confined to the liver were treated with L-PAM dosages escalating from 0.5 to 4.0 mg kg(-1). During all IHP procedures, leakage of perfusate was monitored. Duration of IHP was aimed at 60 min, but was shortened in eight cases as a result of leakage from the isolated circuit. From these, three patients developed WHO grade 3-4 leukopenia and two patients died due to sepsis. A reversible elevation of liver enzymes and bilirubin was seen in the majority of patients. Only one patient was treated with 4.0 mg kg(-1) L-PAM, who died 8 days after IHP as a result of multiple-organ failure. A statistically significant correlation was found between the dose of L-PAM, peak L-PAM concentrations in perfusate (R = 0.86, P< or =0.001), perfusate area under the concentration-time curve (AUC; R = 0.82, P<0.001), tumour tissue concentrations of L-PAM (R = 0.83, P = 0.011) and patient survival (R = 0.52, P = 0.02). The peak L-PAM concentration and AUC of L-PAM in perfusate at dose level 3.0 mg kg(-1) (n = 5) were respectively 35- and 13-fold higher than in the systemic circulation, and respectively 30- and 5-fold higher than reported for high dose oral L-PAM (80-157 mg m(-2)) and autologous bone marrow transplantation. Median survival after IHP (n = 21) was 19 months and the overall response rate was 29% (17 assessable patients; one complete and four partial remissions). Thus, the maximally tolerated dose of L-PAM delivered via IHP is approximately 3.0 mg kg(-1), leading to high L-PAM concentrations at the target side. Because of the complexity of this treatment modality, IHP has at present no place in routine clinical practice.  (+info)

A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. (8/241)

There are no satisfactory treatment options for patients with ocular melanoma metastatic to liver, and after liver metastases are identified, median survival is only between 2 and 7 months. Because liver metastases are the sole or life-limiting component of disease in the vast majority of patients who recur, we reasoned that complete vascular isolation and perfusion of the liver might result in clinically meaningful regression of disease. Between September 1994 and July 1999, 22 patients (13 women and 9 men; mean age, 49 years) with ocular melanoma metastatic to liver were treated with a 60-min hyperthermic isolated hepatic perfusion (IHP) using melphalan alone (1.5-2.5 mg/kg, n = 11) or with tumor necrosis factor (TNF, 1.0 mg, n = 11). Via a laparotomy, IHP inflow was via the hepatic artery alone (n = 17) or hepatic artery and portal vein (n = 5) and outflow from an isolated segment of inferior vena cava. Most patients had advanced tumor burden with a mean percentage of hepatic replacement of 25% (range, 10-75%) and a median number of metastatic nodules of 25 (range, 5 to >50). Complete vascular isolation was confirmed in all patients using a continuous intraoperative leak monitoring technique with 131I radiolabeled albumin. There was one treatment mortality (5%). The overall response rate in 21 patients was 62% including 2 radiographic complete responses (9.5%) and 11 partial responses (52%). The overall median duration of response was 9 months (range, 5-50) and was significantly longer in those treated with TNF than without (14 versus 6 months, respectively; P = 0.04). Overall median survival in 22 patients was 11 months. These data indicate that a single 60-min IHP can result in significant regression of advanced hepatic metastases from ocular melanoma. TNF appears to significantly prolong the duration of response.  (+info)

*List of MeSH codes (E04)

... chemotherapy, cancer, regional perfusion MeSH E04.292.451 --- extracorporeal membrane oxygenation MeSH E04.292.465 --- heart ...

*Hyperthermia therapy

Regional hyperthermia heats a larger part of the body, such as an entire organ or limb. Usually, the goal is to weaken cancer ... Hot chemotherapy drugs are pumped directly into the peritoneal cavity to kill the cancer cells. Whole-body hyperthermia heats ... This may use the same techniques as local hyperthermia treatment, or it may rely on blood perfusion. In blood perfusion, the ... It is typically used to treat metastatic cancer (cancer that spread to many parts of the body). Techniques include infrared ...

*Brendon Coventry

... limb infusion is a minimally invasive alternative to isolated limb perfusion for delivering high-dose regional chemotherapy to ... 181m on cancer research grants in 2014, and almost 800 cancer patients per week still die of cancer, or over 40,000 Australians ... When local cancer tumours where injected with the vaccine, cancers that had not been injected began to shrink as well, thus ... innovative and specialist cancer drugs in Australia states that the five-year survival rate of patients with advanced cancer is ...

*Percutaneous hepatic perfusion

... (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing ... PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy. As demonstrated ... Seidel GD, Locklin J, Muehlbauer PM (June 2006). "Part I: regional chematherapy clinical studies in nontraditional clinical ... treated by PHP can tolerate much higher doses of chemotherapeutic agents than those receiving traditional systemic chemotherapy ...

*Delcath Systems

Seidel, Geoffrey D. Part I: Regional Chemotherapy Clinical Studies in Nontraditional Clinical Settings. 10.1188/06.CJON.338-344 ... as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, ... New Jersey Providence Cancer Center in Portland, Oregon St. Luke's Cancer Center of Bethlehem, Pennsylvania Swedish Medical ... primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas Pingpank, James F. ...

*Limb perfusion

... is also used in veterinary medicine, where is it usually referred to as regional limb perfusion (RLP). It is ... Limb perfusion entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public domain material from ... The main purpose of the isolated limb perfusion technique is to deliver a very high dose of chemotherapy, at elevated ... Regional limb perfusion allows drug dose to be reduced while maintaining therapeutic concentrations at the site of interest, ...

*Cerebrospinal fluid

"Intrathecal Chemotherapy for Cancer Treatment , CTCA". CancerCenter.com. Retrieved 22 May 2017. Hajdu SI (2003). "A note from ... This decreases total intracranial pressure and facilitates blood perfusion. Homeostasis: CSF allows for regulation of the ... "Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins". Science. ... Some anaesthetics and chemotherapy are injected intrathecally into the subarachnoid space, where they spread around the CSF, ...

*Index of oncology articles

... refractory cancer - regional cancer - regional chemotherapy - regional enteritis - regional lymph node - regional lymph node ... islet cell cancer - islet of Langerhans cell - isoflavone - isointense - isolated hepatic perfusion - isolated limb perfusion ... cancer induction - Cancer Information Service - cancer of unknown primary origin - Cancer stem cell - cancer vaccine - Cancer. ... local cancer - local therapy - localized gallbladder cancer - locally advanced cancer - lometrexol - lomustine - lonafarnib - ...

*MRI sequence

Coupled with imaging of cerebral perfusion, researchers can highlight regions of "perfusion/diffusion mismatch" that may ... TIRM is superior in the assessment of osteomyelitis and in suspected head and neck cancer. Osteomyelitis appears as high ... chemotherapy and celiac disease. Techniques to suppress fat on MRI mainly include: Identifying fat by the chemical shift of its ... "Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy". Magn ...

*Cell encapsulation

Another approach to cancer suppression is through the use of angiogenesis inhibitors to prevent the release of growth factors ... Microencapsulation is a valuable technique for local, regional and oral delivery of therapeutic products as it can be implanted ... 2003). "Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable ... which stimulate neovascularization and restore perfusion in the damaged ischemic heart. An example of this is shown in the ...

*Hybrid operating room

In case contrast agent has been used to mark the lesion, it will also drain into the regional lymph nodes, which then can be ... Improvements of the C-Arm technology nowadays also enable perfusion imaging and can visualize parenchymal blood volume in the ... 2003). "Performance Characteristics of Different Modalities for Diagnosis of Suspected Lung Cancer *". Chest. 123: 115S-128S. ... chemotherapy (curative approach) or through chemoembolization / ablation (palliative approach) A hybrid operating room supports ...

*Infection

... as might occur following poisoning or cancer chemotherapy), exposure to ionizing radiation, or as a result of an infectious ... In children the presence of cyanosis, rapid breathing, poor peripheral perfusion, or a petechial rash increases the risk of a ... 8 (3). GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex ... Those who are weak, sick, malnourished, have cancer or are diabetic have increased susceptibility to chronic or persistent ...
This phase I/II trial studies the safety, best dose and effectiveness of targeted gene therapy combined with isolated limb infusion (ILI) of melphalan and dactinomycin for treating patients with advanced extremity melanoma that cannot be removed by surgery. Adding gene therapy to a standard chemotherapy regimen in the isolated limb may enhance anti-cancer effects by inducing a systemic immune response against the tumor cells ...
TY - JOUR. T1 - Isolated limb infusion for in-transit malignant melanoma of the extremity. T2 - A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. AU - Beasley, Georgia M.. AU - Petersen, Rebecca P.. AU - Yoo, Jin. AU - McMahon, Nicole. AU - Aloia, Thomas. AU - Petros, William. AU - Sanders, Gretchen. AU - Cheng, Tsung Yen. AU - Pruitt, Scott K.. AU - Seigler, Hilliard. AU - Tyler, Douglas. PY - 2008/8. Y1 - 2008/8. N2 - Background: Isolated limb infusion (ILI) is a recently described minimally invasive technique developed in Australia for delivering regional chemotherapy. This study examined the efficacy and toxicity of ILI, compared to hyperthermic isolated limb perfusion (HILP), in treating extremity in-transit melanoma. Methods: Variables from a prospective single institution database of 120 regionally treated melanoma patients (1995-2007) were compared using chi-square analysis. This included 61 consecutive ILI treatments in 58 patients and 59 HILP ...
TY - JOUR. T1 - Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. AU - Libutti, Steven K.. AU - Bartlett, David L.. AU - Fraker, Douglas L.. AU - Alexander, H. Richard. PY - 2000. Y1 - 2000. N2 - Background: For a variety of histologies, the liver represents the only or the dominant site of metastatic disease. Regional treatment of the liver has the theoretic advantage of maximizing drug delivery while minimizing systemic toxicity. This article describes the technique of isolated hepatic perfusion using tumor necrosis factor and melphalan under conditions of moderate hyperthermia for the treatment of unresectable liver tumors. Study Design: Fifty patients with biopsy-proved unresectable primary or metastatic cancer to the liver were treated. Isolated hepatic perfusion was performed for 60 minutes under conditions of moderate hyperthermia during a laparotomy with inflow through the ...
Patients with pancreatic carcinoma generally have poor prognosis, since it is typically detected too late. Furthermore, it is located near anatomically important structures such as the bile ducts and major blood vessels, which complicates access to the tumor. At the time of diagnosis, only 10% of these tumours are still operable.. For advanced pancreatic carcinoma, chemotherapy only prolongs life expectancy in the range of 2 to 6.5 months. Patients previously treated with radiation and chemotherapy are rarely included in the studies because of their poor prognosis. As a result, very few such studies exist. One study (Author: Berlin JD et al) reports a median survival time (50%) of 6.7 months in a large group of 322 previously treated patients, and a 25% survival period of 10.5 months.. More recent studies of advanced, inoperable pancreatic carcinoma using newer agents could not demonstrate greater than 20-25% survival rate beyond one year. Regional chemotherapy for regionally advanced, ...
The study, conducted over a 22-year period from 1994 to 2016, is the largest one to date of limb preservation using isolated limb infusion for sarcoma. "Advocates for [isolated limb infusion] in these patients would argue that, with similar long-term survival data and meaningful overall response rates, patients would much prefer a treatment that preserves the affected extremity to one that does not," Dr. Mullinax said. Isolated limb infusion has historically been used primarily for melanoma of the extremities, and the use of this technique in sarcoma is a novel approach. Sarcoma is a rare type of cancer in the extremities with several different subtypes; the study patients who underwent isolated limb infusion had 17 different subtypes of sarcoma ...
Abstract Purpose: Isolated limb perfusion (ILP) with hyperthermia is an effective treatment for in-transit metastases of malignant melanoma in the extremities. Preclinical studies have shown that hyperthermia may induce an immunogenic death of tumour cells. We therefore decided to study whether ILP may induce tumour-specific immune responses in the clinical setting. Method: The number of Melan-A/Mart-1 specific CD8+ T cells, as well as other phenotypically different immune cells, was recorded in peripheral blood in 12 HLA-A2+ patients with in-transit metastases undergoing hyperthermic ILP with melphalan. Results: All patients underwent ILP without any complication and with an overall response rate of 83%. No substantial changes in the number of circulating T-cells, B-cells, NK-cells or monocytes were observed during follow-up. Four out of 12 patients showed an elevation of Melan-A+ CD8+ T-cells 4 weeks after ILP. Conclusion: We here report our preliminary observations that a small increase in ...
Background There is increasing evidence that tumor hypoxia plays a significant role in the chemoresistance of melanoma, but to our knowledge, real-time tumor oxygenation during isolated limb infusion...
This talk will focus on the current literature associated with regional limb perfusion and provide technical details of performing regional limb perfusions in the field. In addition, cases and indications of use will be discussed along with common pitfalls or failures seen with the procedure that may lead to a failure in response to treatment. There will be a discussion of the prognosis seen with its use verses without. ...
Regional perfusion therapy can be an option for treating metastases which are cancers that started in one part of the body and have spread to an adjacent part.
Find best value and selection for your MANFRED MANNS EARTH BAND Good Earth UK LP 1974 ILPS search on eBay. World's leading marketplace.
Hello All, A review of the Source Hydration ILPS system. For a while now I have been searching for a hydration system to integrate into my LBT 6094 Slick carrier. The idea was is that the Slick being the base system for all my current rigs I would like to keep the hydration on it. Some requiremen...
Percutaneous hepatic perfusion (PHP) is a minimally invasive treatment that delivers high-dose chemotherapy directly to metastatic melanoma in the liver. Unlike traditional chemotherapy, in which medications circulate throughout the entire body, PHP specifically targets the liver only, which can help reduce the side effects commonly associated with chemo. This approach allows oncologists to treat tumors with much higher doses of chemotherapy than would otherwise be possible when given systemically (through the peripheral veins).. At Moffit Cancer Center, percutaneous hepatic perfusion is offered to treat melanoma that has spread to the liver (as often occurs with ocular melanomas), and select other tumors metastatic to the liver. Prior to recommending this therapy to a patient, our oncologists and interventional radiologists will assess a number of factors, including the following, to ensure that PHP is a suitable option:. ...
Background: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis factor a for locally advanced angiosarcoma. Material and methods: All patients who underwent an ILP for angiosarcomas between 1991 and 2016 in three tertiary referral centres were identified from prospectively maintained data-bases. Results: A total of 39 patients were included, with a median follow-up of 18 months (interquartile range 6.1-60.8). Of these patients, 23 (58.9%) patients had a complete response (CR) after ILP, 10 (25.6%) had a partial response, 4 (10.3%) had stable disease and 2 (5.1%) patients had progressive disease immediately after ILP. A total of 22 patients developed local progression (56.4%), whereas nine (23.1%) developed distant metastases. The patients with CR had a significantly prolonged median local progression-free ...
Definition of in-transit metastasis. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
PURPOSE OF REVIEW: The recent discovery of effective systemic treatments for melanoma has dramatically improved the prognosis for patients with advanced disease. As a result, the multidisciplinary management of melanoma has evolved significantly. In the past decades surgery was reserved for symptomatic palliation in patients with metastatic melanoma. Today surgical treatment of patients responding to systemic therapies has become an integral part of disease control. RECENT FINDINGS: Current efforts are focused on minimizing the morbidity of surgery (laparoscopic inguinal lymph node dissection, selective completion lymphadenectomy) as well as combining surgery with systemic therapy in novel ways (neoadjuvant targeted and/or immunotherapy, isolated limb infusion/perfusion with systemic immunotherapy ...
...NEW YORK Feb. 19 /- Delcath Systems Inc. ...(Logo: ...,Dr.,James,F.,Pingpank,to,Present,at,Leading,Regional,Therapies,Conference,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients Limbs from Amputation (March 16, 2017) Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve... Continue Reading. ...
When treating confined melanoma regional perfusion therapy can be a treatment option for tumors that are confined to a single organ or region of the body.
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an appropriate treatment for select patients with peritoneal carcinomat
A review of 60 consecutive patients with peritoneal carcinomatosis who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC)-sometimes called "hot chemotherapy"-found 0% mortality and 33% morbidity, with "a significant reduction of grade III/IV morbidity, perioperative transfusion, and reintervention rate after 20 procedures." Reporting their results in the Archives of Surgery,1 physicians at the Institut Paoli-Calmettes and Université de la Méditerranée in Marseille, France, noted that the "introduction of the HIPEC program was successful because of the surgical teams prior experience in cytoreductive and cancer operations.". Learning Curve. In an accompanying editorial, Nita Ahuja, MD, agreed: "The message that we can heed here is that experience matters." In a follow-up interview with The ASCO Post, Dr. Ahuja said that there are cytoreduction-with-HIPEC programs with experienced physicians at several centers in the United States (see sidebar). These ...
U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT03111069) titled Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children on April 6. Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of heated doxorubicin that can be given to patients during surgery with abdominal tumors. The safety of this drug will also be studied. Study Start Date: Study Type: Interventional Condition: Malignant Neoplasms of Mesothelial and Soft Tissue Rhabdomyosarcoma, Pelvic Rhabdomyosarcoma, Abdominal Intervention: Procedure: Abdominal Surgery Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease). Unresectable Intra-Abdominal/Pelvic Tumors Group: ...
A recent Phase I clinical trial reported encouraging survival data with respect to the use of maximal cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) using pegylated liposomal doxorubicin (PLD)(e.g., Doxil™) to treat patients with advanced intra-abdominal, gastrointestinal and gynecological malignancies. HIPEC is used in conjunction with surgery and chemotherapy to treat patients with gastrointestinal tract…
Abstract: Advancements in medical technology coupled with a more thorough comprehension of oncologic diseases has resulted in a burgeoning number of aggressive treatment options available to cancer patients and a gradual loosening of the association between cancer and timely death. With the advent of extended life expectancies, however, the need to investigate the human and overall life impact of cancer diseases and treatments has increased dramatically (Langenhoff et al., 2001). This need to examine considerations of quality of life becomes even more essential in the context of high-risk treatments, such as cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC), an extensive procedure offered to select candidates with peritoneal carcinomatosis from a variety of primary origins (Levine et al., 2007). A biopsychosocial model of research and clinical care (e.g. Wilson & Cleary, 1995) underscores the many levels and interrelationships of clinical, demographic, and ...
HIPEC is an aggressive, novel surgical treatment reserved for patients with peritoneal carcinomatosis. It combines extensive removal of cancers, known as surgical cytoreduction, with the intraoperative introduction of chemotherapeutic drugs into the peritoneal cavity at a temperature several degress above normal body temperature. The abdominal cavity is perfused for about 90 minutes, thereby exposing potential microscopic residual cancer cells directly to the synergistic effects of hyperthermia (heat), and cytotoxic agents.. HIPEC is resource-intensive and requires extraordinary surgical and multidisciplinary cooperation. As such, only a few centers nationwide offer patients this option. The Feist-Weiller Cancer Center is the only cancer center in Louisiana that offers HIPEC presently.. HIPEC is used to treat the following types of cancers in its advanced and recurrent stages:. ...
Aims and objectives.To study patients descriptions of their health after cytoreductive surgery (CRS) before discharge.. Background. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) affects the patients recovery. The hospital stay is long, and it is important to study how patients experience their health postoperatively.. Design. Qualitative descriptive design.. Methods. Between January-May 2012, individual interviews were conducted with 20 patients in a university hospital in cen- tral Sweden using a semi-structured interview guide. Data were analysed using qualitative content analysis.. Results. Three themes (a process, body and mind, and support) and nine categories emerged. The surgery was described as a turning point, followed by a period of hope and thankfulness. Nevertheless, patients had difficulty taking in their positive feelings because they were overwhelmed by their bodily ailments. Despite the patients descriptions of being on an emotional roller ...
Discussion: The infection rate in our centre compared to previous studies of comparable patients was matching. Effective management of postoperative infections should be considered, and identified risk factors in this study can help to focus on effective prevention and treatment strategies. PMID: 31467552 [PubMed]...
Splenectomy is an independent risk factor for poorer perioperative outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: an analysis of 936 procedures
The imaging method called positron emission tomography (PET) using the radioactive tracer molecule 18F-FDG is a valuable way to both diagnose and track the progression of malignant peritoneal mesothelioma. Nuclear medicine researchers at a Hospital in Barcelona, Spain reviewed the diagnostic and treatment records of 60 people with malignant peritoneal mesothelioma, a form of mesothelioma that spreads on the membrane lining the walls of the abdomen. The study subjects included 34 women and 26 men with a mean age of 53. All the patients in the study had had multiple 18-F-FDG-PET scans to diagnose or track their cancer. Eleven of the studied patients had an FDG-PET scan prior to receiving treatment. In all cases, the scans showed characteristic mesothelioma disease … Continue reading Tracking Mesothelioma with FDG-PET » ...
Define L-phenylalanine mustard. L-phenylalanine mustard synonyms, L-phenylalanine mustard pronunciation, L-phenylalanine mustard translation, English dictionary definition of L-phenylalanine mustard. n a drug, C13H18Cl2N2O2, used to treat myeloid leukaemia Noun 1. melphalan - antineoplastic drug used to treat multiple myeloma and some other malignancies...
Researchers at Roswell Park Cancer Institute (RPCI) have determined that cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC), a complex procedure to treat advanced abdominal cancers, can be done safely, and may be an effective therapy for select patients. Study results are published in the June issue of Cancer Medicine.
The data were collected in the Medical Spectrum Twente, a large community teaching hospital in the regional capital of a foremost rural area in the eastern part of the Netherlands. It functions as a regional referral center for liver and lung surgery, but has no facilities for the treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy (HIPEC).. The study design is a prospective observational cohort study evaluating the outcome of routine staging with abdominal CT concerning the ability to find liver metastases (LM), peritoneal carcinomatosis (PC) and T4-stage in colon cancer (LACC). All patients in our hospital who where treated for CRC from January 2007 till December 2009 were included in the analysis; all surgical patients with CRC in the study hospital were prospectively registered in a database designed for colorectal surgery, including patient characteristics, staging and surgical procedures, the clinical M stage and pathological TNM stage, post-operative ...
Feist-Weiller Cancer Center. View Dr. Chus CV. Dr. Quyen Chu is a Professor of Surgery and Chief of the Division of Surgical Oncology at LSUHSC at Shreveport. He joined LSUHSC at Shreveport in 2002 after completing a clinical fellowship in surgical oncology at Roswell Park Cancer Institute in Buffalo, NY.. Dr. Chus clinical interests include the management of patients with cancer of the gastrointestinal tract (esophagus, stomach, liver, bile ducts, pancreas, colon and rectum), breast cancer, melanoma, thyroid and parathyroid tumors, and soft tissue tumors (retroperitoneal tumors and extremity sarcomas). He has been instrumental in establishing two life-saving programs: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) program for advanced abdominal malignancies and mammosite for breast cancer patients. He has also helped in the development of novel therapies, such as gene therapy, to treat patients with advanced solid malignancies.. Dr. Chu has coauthored more than 70 publications and six book ...
He also specializes in the treatment of peritoneal-based malignancies using hyperthermic intraperitoneal chemotherapy (HIPEC). Multidisciplinary GI Conference/Clinic. For patients with gastrointestinal cancers, we bring together a highly specialized team to rapidly evaluate each case and develop a consensus treatment plan. This is called a multidisciplinary conference. The purpose is to help speed up the time from diagnosis to treatment. This comprehensive conference includes surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, a genetic counselor, clinical trials nurses, social workers, dietitians and a clinic coordinator.. Patients in the Multidisciplinary Gastrointestinal Oncology Clinic receive comprehensive therapy coordinated within a single clinic, resulting in the delivery of personalized clinical care. We also provide a caring and supportive environment with the help of our nursing staff, nurse practitioners, social workers and dietitians.. ...
Background: Pancreatic cancer is the fourth leading cause of cancer related death in the Western world. At time of diagnosis, 20% of patients present with a resectable tumour, 40% with an irresectable locally advanced tumor (without metastases) and 40% with metastatic disease. The median survival of patients with irresectable locally advanced pancreatic cancer is only 6 months. Currently, there is no effective treatment for these patients Importance: There is an urgent need for new therapeutical options in pancreatic adenocarcinoma. Radiofrequency ablation (RFA) is a technique that has been demonstrated to be effective in the treatment of several irresectable tumours such as liver and lung neoplasms. RFA produces local tumour destruction from an electrode implanted directly into the tumour causing frictional heating. Objective: To evaluate whether endoscopic ultrasound-guided radiofrequency ablation (EUSRFA) plus conventional treatment (chemotherapy ± radiotherapy) improves overall survival in ...
SPIS TREŚCI 2014, Tom XXXVI, Nr 216, CZERWIEC CONTENTS 2014, VOL XXXVI, No. 216, JUNE ARTYKUŁ REDAKCYJNY / EDITORIAL Chronowska J., Łabuzek K., Kukla U., Lekstan A., Okopień B.: 365 Dootrzewnowa chemioterapia perfuzyjna w hipertermii jako nowy sposób leczenia przerzutów nowotworowych do otrzewnej Hyperthermic intraperitoneal chemotherapy as a new way of peritoneal metastases treatment PRACE ORYGINALNE / ORIGINAL PAPERS Pawełczak E., Gaszyński T.: 369 Występowanie nadciśnienia tętniczego w społeczności miejskiej a promowanie zachowań prozdrowotnych The prevalence of hypertension among the urban community and promoting healthy behaviors Jerzykowska S., Cymerys M., Roszak M., Wysocka E., Michalak S., Pupek-Musialik D.: 373 Analiza wpływu krótkotrwałego wysiłku fizycznego na wybrane parametry funkcji śródbłonka naczyniowego oraz sztywność naczyń krwionośnych u młodych i zdrowych mężczyzn The analysis of the influence of short term physical effort on selected
Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.
Group 1 - During laparotomy, after tumor removal, patients receive continuous hyperthermic peritoneal perfusion (CHPP) with the anti-cancer drug cisplatin. For CHPP, the cisplatin solution is heated and delivered to the abdomen through a catheter (plastic tube), washed through the abdomen for 90 minutes, and then drained out of the body through another catheter. At the close of surgery, a small catheter, called a Tenckhoff catheter, is left in the abdomen and brought out through the skin. Between days 7 and 12 after surgery, one dose of fluorouracil and paclitaxel chemotherapy is delivered through this catheter. The catheter is removed following complete recovery from surgery and the patient is discharged from the hospital. Four to 6 weeks after the surgery, patients have CT scans of the chest, pelvis, and abdomen, and then begin intravenous (IV, through a vein) chemotherapy with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin. The chemotherapy is given in 4-week courses as follows: ...
Percutaneous hepatic perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing Phase II and Phase III clinical testing. PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy. As demonstrated in clinical trials, patients treated by PHP can tolerate much higher doses of chemotherapeutic agents than those receiving traditional systemic chemotherapy without increased toxicities. Using a system of catheters and filters, PHP isolates the liver from the circulatory system and infuses a chemotherapeutic agent directly to the liver via the hepatic artery. The venous effluent from the liver is then filtered outside of the body and the filtered blood is returned into the jugular vein. PHP is a repeatable procedure and can be performed in an operating room or a radiology suite under local or general anesthesia. Delcath Systems Business Wire Delcath Systems, Inc. Pingpank JF, Libutti SK, Chang R, et al. ...
• Regional perfusion has been utilized in the treatment of accessible melanomas for many years. This series of 245 patients, which encompasses over ten years of
Cornelis J. H. van de Velde is the author of this article in the Journal of Visualized Experiments: Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
00. Elsevier Masson SAS. Tous droits réservés Gastroenterol Clin Biol 00;:- MÉSOTHÉLIOMES MALINS DU PÉRITOINE ARTICLE ORIGINAL Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery
Given its rarity, there are no established guidelines for the treatment of peritoneal mesothelioma. The modern approach to malignant peritoneal mesothelioma includes cytoreductive surgery,[10] hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy, and intravenous chemotherapy.[11] These are often used in conjunction and in a complementary fashion, and this multifaceted approach has significantly improved outcomes when compared to intravenous chemotherapy alone. For instance, the reported median survival time for patients with stage IV mesothelioma as reported by the American Cancer Society is 12 months;[12] however, with adequate cytoreduction, intraperitoneal, and intravenous chemotherapy combined, some authors report 10-year survival rates projected at nearly 75%.[13]. Multiple factors have been shown to be significant in predicting the outcome and overall survival. Age greater than 60 at surgery, more overall disease burden (defined as a PCI greater than 15), ...
BACKGROUND: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition. METHOD: Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion. RESULTS: A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma ...
Peritoneal surface malignancy (PSM) is a clinical entity with an unfavourable prognosis, which characterizes the evolution of neoplastic diseases from the abdominal and/or pelvic organs and could also be the terminal stage of extra-abdominal tumors. Examples of diseases that can spread mainly within the peritoneal cavity are appendiceal tumors, ovarian cancer, colorectal cancer, abdominal sarcomatosis, gastric cancer and peritoneal mesothelioma. The locoregional therapy is defined as the combination of cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). The rationale of this combined therapy for PSM is based on the natural history of this clinical entity that remains confined in the peritoneal cavity for most of its natural history. This pattern of spread would seem to indicate the potential usefulness of selectively increasing drug concentration in the tumour-bearing area by direct intraperitoneal chemotherapy instillation. This approach led to these outcomes: the ...
It can be difficult to differentiate diffuse malignant peritoneal mesothelioma (DMPM) from reactive mesothelial hyperplasia (RMH) or peritoneal dissemination of gynecologic malignancies, such as epithelial ovarian cancer (EOC), which cause a large amount of ascites. Detection of the homozygous deletion of p16/CDKN2A (p16) by fluorescence in situ hybridization (FISH) is an effective adjunct in the diagnosis of malignant pleural mesothelioma. The aim of this study was to investigate the ability of the p16 FISH assay to differentiate DMPM from RMH and EOC.. ...
TY - JOUR. T1 - Localized malignant peritoneal mesothelioma arising in the mesentery of the ascending colon. AU - Kim, Younghye. AU - Lee, Eunjung. AU - Jung, Wonkyoung. AU - Kim, Han Kyeom. AU - Jung, Soon Hee. AU - Hong, Kwang Dae. AU - Lee, Youngseok. PY - 2012/5/1. Y1 - 2012/5/1. UR - http://www.scopus.com/inward/record.url?scp=84862862365&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84862862365&partnerID=8YFLogxK. M3 - Article. C2 - 22546096. AN - SCOPUS:84862862365. VL - 78. JO - American Surgeon. JF - American Surgeon. SN - 0003-1348. IS - 5. ER - ...
Cancer that spreads to the lining of the abdominal wall is typically lethal within six months. However many patients with this diagnosis are living longer with advanced treatments available at NYP/Columbia - one of the few programs in the nation to perform complex, extensive cytoreduction operations paired with hyperthermic intraperitoneal chemotherapy (HIPEC).
Although flow through portal vein and hepatic artery is readily accessible using Doppler sonography, (22,23) in vivo studies on human hepatic (parenchymal) perfusion are limited due to the often (highly) invasive methodology required. Indirect methods for measuring hepatic blood flow have been used and include the assessment of clearance or dilution of a dye or marker (gas or microspheres), which have a wider range of clinical applicability than the direct methods (38). Moreover, noninvasive measurements of hepatic perfusion using PET with the freely diffusible flow tracer [15O]H2O have been shown to provide reliable estimates of hepatic blood flow, when taking into account the dual input from hepatic artery and vena porta (27,28). In the current study, decreased hepatic parenchymal perfusion was observed in type 2 diabetic patients with increased liver triglyceride content but not in those type 2 diabetic patients with low liver triglyceride content, as compared with control subjects, implying ...
Mr Hayes is a Consultant General Surgeon and Surgical Oncologist at the Sarcoma Unit and the Skin Unit at The Royal Marsden and an Honorary Faculty at the ICR since October 2017.. His pre-clinical training was at Oxford University and his clinical training was at St Bartholomews Hospital, London. He undertook his postgraduate surgical training in London. Mr Hayes spent three years of research training at the Lombardi Cancer Center, Georgetown University Hospital, Washington DC, US, for which he was awarded a PhD in 2001. In 2002, Mr Hayes was awarded a Hunterian Professorship by the Royal College of Surgeons in England for his research into angiogenesis as a therapeutic approach for cancer.. For the last 14 years, Mr Hayes has developed a specialist surgical practice in soft-tissue sarcoma and advanced melanoma. He leads the Isolated Limb Perfusion programme, which provides a national service for regional chemotherapy for patients with advanced limb malignancy. He is currently the Lead ...
In two of the patients surgery was not performed. The scan findings influenced the decision to opt for conservative management in both. They aided the decision to withdraw active treatment in a 7-month-old baby with meningococcal septicaemia, extensive four-limb involvement and neurological damage. In the other, discussed above, conservative treatment was continued and amputation of a leg avoided based on the perfusion findings alone (Fig. 6). The remaining 18 patients proceeded to surgery.. In all cases discussed below, tissue showing no perfusion on the scan was found to be clinically necrotic, while areas showing reduced but present perfusion were found at surgery to be viable. Sixteen patients had surgical intervention in one or both lower limbs. In two cases (three legs) the scanned level of perfusion correlated with the extent of necrosis found at surgery, but the level of amputation had to be higher for anatomical and functional reasons. In the remaining 14 patients (28 lower limbs) the ...
The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma. ...
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type and stage of the cancer being treated. Combination chemotherapy is treatment using more than one anticancer drug. ...
On the connection between the phase transition of the covering test and the learning success rate in ILP - It is well-known that heuristic search in ILP is prone to plateau phenomena. An explanation can be given after the work of Giordana and Saitta: the ILP covering test is NP-complete and therefore exhibits a sharp phase transition in its coverage probability. As the heuristic value of a hypothesis depends on the number of covered examples, the regions yes and no represent plateaus that need to be crossed during search without an informative heuristic value. Several subsequent works have extensively studied this finding by running several learning algorithms on a large set of artificially generated problems and argued that the occurrence of this phase transition dooms every learning algorithm to fail to identify the target concept. We note however that only generate-and-test learning algorithms have been applied and that this conclusion has to be qualified in the case of data-driven learning
Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.
Primary peritoneal neoplasms comprise an uncommon group of heterogenous entities. The list includes: mesothelial derivatives primary (malignant) peritoneal mesothelioma primary peritoneal multicystic mesothelioma primary peritoneal well-diff...
A clinical case of the treatment of a patient with metastatic inoperable liver cancers with the use of radiofrequency ablation combined with regional chemotherapy and chemoembolization
https://doi.org/10.18632/oncotarget.12383 Ting Yang, Qiaoxian Lin, Jinhua Ren, Ping Chen, Xiaohong Yuan, Xiaofeng Luo, Tingbo Liu, Jing Zheng, Zhihong Zheng, Xiaoyun Zheng, Xinji Chen, Langhui Zhang,...
PURPOSE: We aimed to determine the intra- and interobserver agreement on the software analysis of very low dose hepatic perfusion CT (pCT).. METHODS: A total of 53 pCT examinations were obtained from 21 patients (16 men, 5 women; mean age, 60.4 years) with proven liver metastasis from various primary cancers. The pCT examinations were analyzed by two readers independently and perfusion parameters were noted for whole liver, whole metastasis, metastasis wall, and normal-looking liver (liver tissue without metastasis) in regions of interest (ROIs). Readers repeated the analysis after an interval of one month. Intra- and interobserver agreements were assessed with intraclass correlation coefficients (ICC) and Bland-Altman statistics.. RESULTS: The mean ICCs of all ROIs between readers were 0.91, 0.93, 0.86, 0.45, 0.53, and 0.66 for blood flow (BF), blood volume (BV), permeability, arterial liver perfusion (ALP), portal venous perfusion (PVP) and hepatic perfusion index (HPI), respectively. The mean ...
Doxorubicin versus CYVADIC versus doxorubicin plus ifisfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group ...
Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma. Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5-6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3-6 months. Side effects were evaluated according to CTCAE 4.0. Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects,CTCAE grade 2 were noted. All patients reported stabilization or improvement of ...
Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma. Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5-6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3-6 months. Side effects were evaluated according to CTCAE 4.0. Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects,CTCAE grade 2 were noted. All patients reported stabilization or improvement of ...
Indications for GD-HIPEC 1. Intra-peritoneal (abdominal cavity) HIPEC 1). Patients with malignant ascites, which could be the metstatic cancer from the followings: Pseudomyxoma Peritoneal mesothelioma Stamoch cancer, Colorectal cancer Ovarian...
The primary objective of the study is to increase by 15% the complete macroscopic resection rate of predominantly liver metastases from metastatic color
An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-Tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007 ...
Purpose of reviewDespite a significant increase in the utilization of donors after circulatory death (DCD), the number of organs recovered and their function are largely inferior to those from donors after brain death. This review summarizes recent advances in in-situ normothermic regional perfusion
Background: Isolated hepatic perfusion (IHP) is a treatment option for patients with liver metastases. Previous studies have found that liver toxicity is one of the limiting factors, and in an attempt to reduce the toxicity a buffering agent was added to the perfusate. The aim was to retrospectively analyse if this buffering reduced toxicity and complication rates.Methods: A retrospective review of 52 consecutive patients with uveal melanoma liver metastases treated with IHP between 2005 and 2013. Patients were followed by daily liver function tests (LFT). Toxicity was graded according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE; United States Department of Health & Human Services, Washington, D.C), complications according to Clavien-Dindo and response according to RECIST-criteria.Results: Thirty-six patients were treated with a buffered perfusate and 16 patients without buffer. There was no difference in age, gender, largest tumour size or number of tumours between the ...
Search Indian Alphalan Melphalan Manufacturers and Suppliers Details - Contact to Alphalan Melphalan Exporters in India, Alphalan Melphalan Wholesalers, Alphalan Melphalan Distributors and Traders from India.
On July 5, I was on Xinhua South Road watching as rioters smashed and looted. More than 100 people gathered and dispersed in an extremely organized manner, all of them wearing athletic shoes. Based on their accents, most were from the area around Kashgar and Hotan, but I did not see any of them carrying knives. I suspect they were from the ILP because of their slogans. The rioters were shouting "Han get out!" [and] "Kill the Han!" Other than these [slogans], there was also "We want to establish an Islamic country and strictly implement Islamic law." One of the main goals of the ILP is to restore the combined political and religious authority of the Islamic state and strictly implement Islamic law; it is a fundamentalist branch.This organization is extremely disciplined and its composition rather unusual. It attracts young men around the age of 20, mostly from rural areas. In fact, this organization is extremely backwards, so that even among Uyghurs without any basic social underpinning, those ...
Alkeran tablets and injection contain the active ingredient melphalan, which is a type of chemotherapy medicine to treat cancer called an alkylating agent.
Notwithstanding the way that a growing number of tumor bosses have created as treatment pioneers for peritoneal afflictions starting late, the total number of specialists stays little. If there are no peritoneal experts contiguous, you may need to look for one in a neighboring state.. Treatment choices for peritoneal mesothelioma consolidate surgery, chemotherapy, radiation treatment and mix treatment. Masters think joining standard prescriptions routinely works better than any single treatment. A blend of one or more prescriptions is called multimodal treatment. Research exhibits that a multimodal treatment approach ordinarily offers the best change similarly as survival.. The most promising treatment for peritoneal mesothelioma may be warmed intraperitoneal chemotherapy (HIPEC), a multimodal treatment that joins surgery and warmed chemotherapy. While experts simply give HIPEC on a case-by-case premise, it has exhibited awesome results for select patients with respect to intensified survival ...
Correlation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary ...
TY - JOUR. T1 - Could texture features from preoperative ct image be used for predicting occult peritoneal carcinomatosis in patients with advanced gastric cancer?. AU - Kim, Hae Young. AU - Kim, Young Hoon. AU - Yun, Gabin. AU - Chang, Won. AU - Lee, Yoon Jin. AU - Kim, Bohyoung. PY - 2018/3. Y1 - 2018/3. N2 - Purpose To retrospectively investigate whether texture features obtained from preoperative CT images of advanced gastric cancer (AGC) patients could be used for the prediction of occult peritoneal carcinomatosis (PC) detected during operation. Materials and methods 51 AGC patients with occult PC detected during operation from January 2009 to December 2012 were included as occult PC group. For the control group, other 51 AGC patients without evidence of distant metastasis including PC, and whose clinical T and N stage could be matched to those of the patients of the occult PC group, were selected from the period of January 2011 to July 2012. Each group was divided into test (n = 41) and ...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
Procedures to provide interventional implantation of a port catheter system into the hepatic artery and adjacent regional chemotherapy of the liver are
This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS). Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 was injected percutaneously into tumors at 53.3 g/L. Dose escalation was based on four levels equivalent to 2.5%, 5%, 10%, and 20% of baseline TV. NBTXR3 was visualized in the tumor 24 hours postinjection, and EBRT was initiated (50 Gy over 5 weeks).
Goggin JM, Hoskinson JJ, Carpenter JW, et al. Vet Radiol Ultrasound 1997;38:211-220. To assess the role of scintigraphic evaluation of distal limb perfusion,
NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from the market for the treatment of advanced soft tissue sarcoma (STS). Lillys actions to withdraw Lartruvo from the market follow the failure of the Phase 3 ANNOUNCE clinical trial, in which Lartruvo did not improve survival for patients. Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market. The program will be established as allowed by local country regulations.. Lilly is working to ensure that patients who are currently receiving Lartruvo may, in consultation with their physician, continue their course of therapy if they have been informed of the risks of Lartruvo and the results of the ANNOUNCE study and wish to continue, subject to local laws and regulations. No new patients should receive Lartruvo outside of participation in ongoing clinical trials. Lilly also is working to ...
Votrient is a tyrosine kinase inhibitor that is used for the treatment of advanced renal cell carcinoma, and advanced soft tissue sarcoma in patients who have received other cancer...
Dr. Veerapong is an expert in combining surgery and heated chemotherapy. HIPEC is affective in helping to improve the prognosis of peritoneal mesothelioma.
Cytoreductive Surgery (CRS) defined as removal of macroscopic abdominal and peritoneal disease, combined with hyperthermic perioperative chemotherapy (HIPEC) is the treatment indicated for pseudomyxoma peritonei (PMP) and appendiceal neoplasms with peritoneal metastases.. CRS and HIPEC should now be considered as the standard of care for selected patients with peritoneal mesothelioma and moderate to small volume peritoneal metastases secondary to colorectal cancer.. Patients who have ovarian or advanced peritoneal metastases from gastric cancer may profit from this strategy but additional evidence should be generated from ongoing collaborative studies at experienced treatment centers.. Further evaluation of neo-adjuvant intraperitoneal, systemic chemotherapy and cytoreductive surgery with HIPEC is required for patients with peritoneal metastases from gastric cancer.. CRS and HIPEC should be avoided in patients who are unlikely to undergo a complete or near-complete resection, or - due to ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
The meta-analysis of data from 53 studies including 6,885 patients with stage III-IV epithelial ovarian cancer who underwent cytoreductive surgery followed by cisplatin or carboplatin-based chemotherapy showed that percent maximal cytoreduction was an independent prognostic variable for survival (P ,0.001) [2]. Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival. It is noteworthy that median survival time was 23.0 months for patients who had maximal cytoreductive surgery rate of 25% or less compared to 36.8 months for those in which maximal cytoreductive surgery was achieved in more than 75% of cases. The present study confirms that optimal surgical cytoreduction is the most important prognostic factor for advanced epithelial ovarian cancer [2-5, 7, 10, 17]. All attempts should be made to achieve complete cytoreduction, but when this result is not achievable, the surgical goal should be al least a residual disease , 1 cm [7]. Optimal cytoreduction ...
Results from a recent study show advances in therapy are significantly boosting survival rates for peritoneal mesothelioma patients.
The way the radiation therapy is given depends on the type of the cancer being treated. External radiation therapy is used to treat pituitary tumors.. Drug therapy. Drugs may be given to stop a functioning pituitary tumor from making too many hormones.. Chemotherapy. Chemotherapy may be used as palliative treatment for pituitary carcinomas, to relieve symptoms and improve the patients quality of life. Chemotherapy uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). The way the chemotherapy is given depends on the type of the cancer being treated. New types of treatment are ...
Although multimodal management of extremity soft tissue sarcoma (STS) is the standard of care, considerable variation exists in the sequencing of radiotherapy (RT) or chemotherapy (CT). Our goal was t
Recurrent melanomas are more likely to found by patient than by routine imaging, study findsRelated items from OnMedicaMelanoma diagnoses hit 10,000 a year for over 55sSome ED drugs linked to raised risk of melanomaED drugs unlikely to increase malignant melanoma riskVirus therapy for melanoma Immunotherapy drug combo curbs melanoma advance from OnMedica News http://ift.tt/2kWHpqR via…
In the week following Britains exit from Europe after the BREXIT referendum, BAUS 2016 got underway in Liverpools BT convention Centre. This was the 72nd meeting of the British A[...] ...
Expertise, Disease and Conditions: Bile Duct Cancer, Bile Duct Disease, Bile Duct Repair, Bile Duct Surgery, Bile Duct Tumors, Biliary Tract Surgery, Biliary Tree, Colorectal Metastases to the Liver, Distal Pancreatectomy, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal Diseases, Hepatic Surgery, Hepatobiliary Disease, Hepatobiliary Malignancies, Hepatobiliary Surgery, Hepatocellular Cancer, Hepatopancreatobiliary Surgery, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Klatskin Tumors, Laparoscopic Adrenal Surgery, Laparoscopic Cholecystectomy, Laparoscopic Gallbladder Surgery, Laparoscopic Liver Surgery, Laparoscopic Pancreas Surgery, Liver Cancer, Liver Cysts, Liver Tumors, Minimally Invasive Surgery, Neuroendocrine Tumors, Pancreatic Cancer, Pancreatic Cysts, Pancreatic Disease, Pancreatic Surgery, Pancreatic Tumors, Pancreaticoduodenectomy, Retroperitoneal Sarcomas, Robotic Bilary Surgery, Robotic Liver Surgery, Robotic Pancreas Surgery, Stomach Cancer, ...
Expertise, Disease and Conditions: Bile Duct Cancer, Bile Duct Disease, Bile Duct Repair, Bile Duct Surgery, Bile Duct Tumors, Biliary Tract Surgery, Biliary Tree, Colorectal Metastases to the Liver, Distal Pancreatectomy, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal Diseases, Hepatic Surgery, Hepatobiliary Disease, Hepatobiliary Malignancies, Hepatobiliary Surgery, Hepatocellular Cancer, Hepatopancreatobiliary Surgery, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Klatskin Tumors, Laparoscopic Adrenal Surgery, Laparoscopic Cholecystectomy, Laparoscopic Gallbladder Surgery, Laparoscopic Liver Surgery, Laparoscopic Pancreas Surgery, Liver Cancer, Liver Cysts, Liver Tumors, Minimally Invasive Surgery, Neuroendocrine Tumors, Pancreatic Cancer, Pancreatic Cysts, Pancreatic Disease, Pancreatic Surgery, Pancreatic Tumors, Pancreaticoduodenectomy, Retroperitoneal Sarcomas, Robotic Bilary Surgery, Robotic Liver Surgery, Robotic Pancreas Surgery, Stomach Cancer, ...
Contact the Boston law firm of Thornton Law Firm at 1-888-491-9726 for a free consultation with Massachusetts most successful mesothelioma attorneys.
The two-year training program emphasizes a strong clinical experience in advanced, state-of-the-art oncologic surgical techniques and multi-disciplinary clinical decision making. The Division of Surgical Oncology has a major interest in the management of advanced malignancies including primary and secondary liver, biliary, pancreatic, colorectal, head and neck, breast, gastroesophageal, endocrine, and soft tissue tumors. A special emphasis is placed on foregut malignancies and regional therapy. There is also interest in biologic response modifiers used with or without chemotherapy, as well as novel immunotherapy strategies.. Our faculty members have a broad experience in regional chemotherapy for visceral tumors (liver and pancreas), melanoma, sarcoma, and inoperable pelvic tumors. The Divisions of Surgical Oncology, Medical Oncology, Radiation Oncology and Interventional Radiology participate in the multi-disciplinary management of our patients. These interactions also involve several ongoing ...
The time course of energy metabolism has been studied in weight-stable and nongrowing mice with a transplantable methylcholanthrene-induced sarcoma.. Daily oxygen consumption and carbon dioxide production were measured in relation to the tumor growth from the time of tumor implantation. The time course of energy dynamics was related to the end-state changes in body composition. Freely fed sarcoma-bearing mice decreased their whole-body energy expenditure in proportion to the tumor growth. This was due to the accompanying anorexia. The alteration in oxygen consumption and carbon dioxide production was continuously evident 24 hr/day in sarcoma-bearing mice. The tumor-bearing mice lost body fat and had decreased respiratory quotient, while pair-fed controls maintained their body composition, and their respiratory quotients agreed with the food respiratory quotient. Loss of body lipids in freely fed sarcoma-bearing mice reflected a negative energy balance, accompanied with increased fat oxidation, ...
There are about 3,000 new cases of mesothelioma each year in the U.S., and only about 300 of those are peritoneal mesothelioma, which forms in the lining of the abdomen. Most cases of mesothelioma result decades after exposure to asbestos or radiation therapy. But in rare cases, young patients who have never been exposed to either risk factor are diagnosed with the disease. One such case led Chirieac and his colleagues to their unexpected finding.. This was a serendipitous discovery. We had a young patient with peritoneal mesothelioma that was difficult to diagnose. We extended our molecular diagnostics to test for a genetic rearrangement that had been reported in lymphoma and lung cancer, but never in mesothelioma. When it came back positive, we were intrigued, said first author Yin (Rex) Hung, MD, PhD, the Corson Thoracic Pathology Fellow in the Department of Pathology at BWH and HMS.. Hung and Chirieac collaborated with other physicians and scientists at BWH and Massachusetts General ...
The procedure of diagnosing peritoneal mesothelioma is like that of different sorts. It begins with a careful examination of your medicinal history, word related history, and general physical condition, trailed by a progression of tests including imaging sweeps and biopsies.. Make sure to say any history of asbestos presentation, regardless of the fact that your specialists neglect to inquire. Its essential to share everything about can incorporated, the dates the episodes happened and the length and span of the exposures. This data will caution your specialists about the likelihood of an asbestos-related sickness and offer them some assistance with determining the suitable next steps.. Since this growth is so uncommon, specialists who need involvement with the ailment frequently misdiagnose mesothelioma patients with more regular diseases who have comparative side effects - a genuine error that defers legitimate treatment. Peritoneal mesothelioma manifestations like stomach swelling, weight ...
Peritoneal mesothelioma is known only to be caused by exposure to asbestos, a microscopic natural fiber that was used heavily in industry. Asbestos is said to reach the abdominal wall by one of two methods. The first is through ingested asbestos fibers which are processed through digestion and become lodged in the peritoneum. The other method is through the lungs and lymph nodes by inhaled asbestos fibers. Malignant mesothelioma of the pleura is also known to metastasize directly into the abdominal cavity if its spread is not slowed.. Many of those who have worked with asbestos materials have developed peritoneal mesothelioma as a result of exposure to friable asbestos fibers. Asbestos was used in a myriad of industrial materials and construction products. Exposure to asbestos was common in aluminum plants, steel mills, power plants, and naval shipyards.. Peritoneal mesothelioma is a relatively rare disease, with only 200-500 diagnoses each year in the United States being documented. Risk, ...

Adult Soft Tissue Sarcoma Treatment (PDQ®): Treatment - Patient Information [NCI] | PeaceHealthAdult Soft Tissue Sarcoma Treatment (PDQ®): Treatment - Patient Information [NCI] | PeaceHealth

... cancer) cells form in the soft tissues of the body. The soft tissues of the body include the muscles, tendons (bands of fiber ... Isolated limb perfusion: A procedure that sends chemotherapy directly to an arm or leg in which the cancer has formed. The flow ... Regional chemotherapy. Clinical trials are studying ways to improve the effect of chemotherapy on tumor cells, including the ... Chemotherapy. Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the ...
more infohttps://www.peacehealth.org/medical-topics/content/nci/ncicdr0000258102.html

Adult Soft Tissue Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Auburn Community HospitalAdult Soft Tissue Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Auburn Community Hospital

Role of regional hyperthermia The use of regional hyperthermia to enhance the local effects of systemic chemotherapy in the ... Role of isolated limb perfusion Isolated limb perfusion is under investigation as a means to deliver high doses of chemotherapy ... American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. Available online. Last ... Cancer Invest 13 (1): 86-95, 1995.. * Grobmyer SR, Maki RG, Demetri GD, et al.: Neo-adjuvant chemotherapy for primary high- ...
more infohttp://www.auburnhospital.org/patient-education/hw-view.php?DOCHWID=ncicdr0000062820

Chemotherapy, cancer, regional perfusion - definition of Chemotherapy, cancer, regional perfusion by The Free DictionaryChemotherapy, cancer, regional perfusion - definition of Chemotherapy, cancer, regional perfusion by The Free Dictionary

... cancer, regional perfusion. Chemotherapy, cancer, regional perfusion synonyms, Chemotherapy, cancer, regional perfusion ... cancer, regional perfusion translation, English dictionary definition of Chemotherapy, cancer, regional perfusion. n. 1. The ... treatment of cancer using specific chemical agents or drugs that are selectively destructive to malignant cells and tissues. 2 ... Chemotherapy, cancer, regional perfusion - definition of Chemotherapy, cancer, regional perfusion by The Free Dictionary https ...
more infohttps://www.thefreedictionary.com/Chemotherapy%2C+cancer%2C+regional+perfusion

Determination of Blood Volume & Application to Regional Perfusion in Chemotherapy | Cancer Council VictoriaDetermination of Blood Volume & Application to Regional Perfusion in Chemotherapy | Cancer Council Victoria

Determination of Blood Volume and Its Application to Regional Perfusion in Chemotherapy Lead researcher. V C Marshall ... News from Cancer Council Victoria and stories of those affected by cancer. ... Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would ... Cancer is a disease of the cells, which are the bodys basic building blocks. ...
more infohttps://www.cancervic.org.au/research/projects/project_determination_of_blood.html

Dan-Arin Silasi, MD | Yale School of MedicineDan-Arin Silasi, MD | Yale School of Medicine

Chemotherapy, Cancer, Regional Perfusion. *Laparoscopy. *Precancerous Conditions. *Gynecologic Surgical Procedures. * ... or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy ... Primary Peritoneal Cancer or Fallopian Tube Cancer Ovary. A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The ... In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer ...
more infohttp://medicine.yale.edu/intranet/facultybydept/dan-arin_silasi-3.profile

Academic Programs Faculty -  Last Initial L - Wake Forest School of MedicineAcademic Programs Faculty - Last Initial L - Wake Forest School of Medicine

Peritoneal Neoplasms; Hyperthermia, Induced; Chemotherapy, Cancer, Regional Perfusion; Adenocarcinoma; Antineoplastic Combined ... Lymphoma, Non-Hodgkin; Antineoplastic Combined Chemotherapy Protocols; Hemangiopericytoma; Meningioma; Antiretroviral Therapy, ...
more infohttp://www.wakehealth.edu/School/FacultySR.htm?st=L&li=L&ft=R

Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF...Hyperthermic Isolated Limb Perfusion in Locally Advanced Soft Tissue Sarcoma and Progressive Desmoid-Type Fibromatosis with TNF...

Background In a prior randomized phase II trial comparing hyperthermic isolated limb perfusion (HILP) with four different doses ... Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.CrossRefPubMedGoogle ... Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha. J Exp Clin Cancer Res. 2004;23:225-31. ... European Organization for Research and Treatment of Cancer Institute of the United States, National Cancer Insitute of Canada. ...
more infohttps://link.springer.com/article/10.1245%2Fs10434-009-0733-9

benign mesothelioma of the pleura 2005:2010[pubdate] *count=100 - BioMedLib™ search enginebenign mesothelioma of the pleura 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced. * ... Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research ... consumer health - Testicular Cancer.. *[Email] Email this result item Email the results to the following email address: [X] ... Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]. *[Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001] ...
more infohttp://www.bmlsearch.com/?kwr=benign+mesothelioma+of+the+pleura+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

childhood kidney cell carcinoma drug 2000:2010[pubdate] *count=100 - BioMedLib™ search enginechildhood kidney cell carcinoma drug 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Mitomycin / administration & dosage. Peritoneal Neoplasms / ... Cites] Pediatr Blood Cancer. 2004 Nov;43(6):668-73 [15390293.001]. *[Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [ ... Cites] Pediatr Blood Cancer. 2008 Mar;50(3):594-8 [17514733.001]. *[Cites] Pediatr Blood Cancer. 2004 May;42(5):427-32 [ ... Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research ...
more infohttp://www.bmlsearch.com/?kwr=childhood+kidney+cell+carcinoma+drug+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

Isolated Limb Perfusion in the Treatment of Advanced Soft-tissue Sarcomas | Springer for Research & DevelopmentIsolated Limb Perfusion in the Treatment of Advanced Soft-tissue Sarcomas | Springer for Research & Development

Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-31.PubMedGoogle Scholar ... Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977;185:555-64PubMedGoogle Scholar ... Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet. 1969;129:305-8.PubMedGoogle ... Results of regional isolation perfusion with cytostatics in patients with soft-tissue tumors of the extremities. Cancer. 1989; ...
more infohttps://rd.springer.com/chapter/10.1007/0-306-48407-2_4

February 2016 - Volume 27 - Issue 2 - Contributor Index : Anti-Cancer DrugsFebruary 2016 - Volume 27 - Issue 2 - Contributor Index : Anti-Cancer Drugs

Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ... Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of ...
more infohttps://journals.lww.com/anti-cancerdrugs/pages/contributorindex.aspx?year=2016&issue=02000

Armed antibodies for cancer treatment: a promising tool in a changing era | SpringerLinkArmed antibodies for cancer treatment: a promising tool in a changing era | SpringerLink

Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal ... Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29A(4):606-612PubMedCrossRef ... Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: ... Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80(1- ...
more infohttps://link.springer.com/article/10.1007/s00262-014-1621-0

Dr. Edward A. LevineDr. Edward A. Levine

Levine continues to research chemotherapy, cancer, regional perfusion, peritoneal neoplasms, and antineoplastic combined ... abdominal cancer, peritoneal carcinomatosis, hyperthermic intraperitoneal chemotherapy (HIPEC), colorectal cancer, sentinel ... esophageal tumors/cancer, peritoneal carcinomatosis, and gastrointestinal cancers. ... The Mesothelioma.com editorial team works hard to offer current, factual, expert reviewed information about mesothelioma cancer ...
more infohttps://www.mesothelioma.com/treatment/doctors/dr-edward-a-levine/

The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion...The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion...

... study was to determine the effect of mild hyperthermia on tumor response and angioneogenesis in an isolated limb perfusion ... Creech OJ, Krementz ET, Ryan RF, Winblad JN: Chemotherapy of cancer: Regional perfusion utilizing an extracorporal circuit. Ann ... Prerequisites for effective isolated limb perfusion using tumor necrosis factor alpha and melphalan in rats. Br J Cancer. 1999 ... Cancer. 1992, 70: 2192-202.View ArticlePubMedGoogle Scholar. *. Ichihara F, Kono K, Sekikawa T, Matsumoto Y: Surgical stress ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-4-53

Docphin | Medical Research Articles Published in September 1962 | Page 2 of 2Docphin | Medical Research Articles Published in September 1962 | Page 2 of 2

An appraisal of cancer chemotherapy by regional perfusion. (PubMedID: 14459555) Annals of Surgery ... Selective heating and cooling of tissue in cancer chemotherapy. (PubMedID: 13912029) Annals of Surgery ... The chemotherapy and epidemiology of tuberculosis. Some findings of general applicability from the Tuberculosis Chemotherapy ... Adrenal function in cancer of the lung, with and without Cushings syndrome. (PubMedID: 14450347) American Journal of Medicine ...
more infohttps://www.docphin.com/medical-research-articles-published-in-month?month=9&year=1962&page=2

Search Articles | University of Toronto LibrariesSearch Articles | University of Toronto Libraries

chemotherapy, adjuvant (9) 9 Filter by. Remove filter. chemotherapy, cancer, regional perfusion (9) 9 ... Cancer , Diseases , Medical imaging , Oncology , Metastasis , FDA approval , Kinases , Cancer therapies , Survival , Skin ... Chemotherapy , Immunotherapy , Oncology, Experimental , Metastasis , Research , Cancer , Index Medicus ... METASTASIS , CANCER CELLS , BIOCHEMISTRY & MOLECULAR BIOLOGY , E-CADHERIN , MALIGNANT-MELANOMA , BREAST , CELL BIOLOGY , ...
more infohttps://query.library.utoronto.ca/index.php/search/q?kw=Author:Santinami,%20Mario

List of MeSH codes (E04) - WikipediaList of MeSH codes (E04) - Wikipedia

... chemotherapy, cancer, regional perfusion MeSH E04.292.451 --- extracorporeal membrane oxygenation MeSH E04.292.465 --- heart ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(E04)

RePub, Erasmus University Repository:
  Improved antitumor response to isolated limb perfusion with tumor necrosis factor after...RePub, Erasmus University Repository: Improved antitumor response to isolated limb perfusion with tumor necrosis factor after...

Animals, Antineoplastic Agents/*administration & dosage, Chemotherapy, Cancer, Regional Perfusion/methods, Cytokines/genetics/* ... In an extremity perfusion model in tumor-bearing rats, we measured response rates to TNF therapy. RESULTS: Functional EMAP-II ... Results of the TNF perfusions in rats suggest that this tumor is more sensitive to TNF therapy. CONCLUSIONS: EMAP-II is ... Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte- ...
more infohttps://repub.eur.nl/pub/9996

مستشفى Medias في بورغهاوزن التقارير الصحفية والمطبوعات  - medias-klinikum.deمستشفى Medias في بورغهاوزن التقارير الصحفية والمطبوعات - medias-klinikum.de

Positive results of regional perfusion chemotherapy for progressive and refractory ovarian cancer made public today. Hypoxic ... Medias Klinikums Recent Results Reinforce and Extend the Positive Effects of Regional Chemotherapy for HN Cancer. Results from ... Favorable results from an ongoing study of regional chemotherapy for pleural mesothelioma presented at the 59th Congress of the ... an ongoing phase-II-study of intra-arterial infusion chemotherapy for HN cancer published in the Journal of Cancer Research and ...
more infohttps://www.medias-klinikum.de/sa/presse.html

NAVER Academic > Search...NAVER Academic > Search...

Cancer, Regional Perfusion, Diagnostic Errors,... ... Chemotherapy, ... Metastatic and histologic presentations in unknown primary cancer.. 1977 J S Nystrom et al. Seminars in Oncology (ScienceDirect ... Mechanisms and prevention of cancer dissemination: an overview.. 1977 E V Sugarbaker et al. Seminars in Oncology (ScienceDirect ...
more infohttps://academic.naver.com/search.naver?field=3&query=Seminars+in+Oncology+%28ScienceDirect%29+4%EA%B6%8C+1%ED%98%B8

Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal...Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal...

Cancer Treatment. Chemotherapy. Regional Therapy. Surgery. Additional relevant MeSH terms: Layout table for MeSH terms. ... The disease has a marked propensity for loco-regional spread and will be the sole or major site of disease in up to 80% of ... The disease has a marked propensity for loco-regional spread and will be the sole or major site of disease in up to 80% of ... Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability. Acta Med Austriaca. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT00001332

NAVER Academic > Search...NAVER Academic > Search...

1985 W P Fontijne et al. Cancer cited 0 times Adult, Aged, Blood Pressure, Chemotherapy, Cancer, Regional Perfusion, methods, ... Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study.FREE. ... Survival of cancer patients by economic status in a free care setting.. 1985 W Keirn et al. Cancer cited 0 times ... Influence of oral contraceptives on the prognosis of breast cancer in young women.. 1985 D Rosner et al. Cancer cited 0 times ...
more infohttps://academic.naver.com/search.naver?field=3&query=Cancer+55%EA%B6%8C+7%ED%98%B8

Swedish experience with peritonectomy and HIPEC : HIPEC in peritoneal carcinomatosisSwedish experience with peritonectomy and HIPEC : HIPEC in peritoneal carcinomatosis

Adolescent, Adult, Aged, Antineoplastic Agents/*administration & dosage, Chemotherapy; Cancer; Regional Perfusion, Humans, ... Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian ... Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion. RESULTS ... BACKGROUND: Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients ...
more infohttp://uu.diva-portal.org/smash/record.jsf?pid=diva2:44556

Overview | Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver...Overview | Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver...

Evidence-based recommendations on chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for ... Regional hepatic arterial delivery of high-dose chemotherapy with isolated hepatic perfusion used to be done using open ... Liver cancers Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic ... Treatment for primary or metastatic liver cancer depends on the location and stage of the cancer and how well liver function is ...
more infohttps://www.nice.org.uk/guidance/ipg488

Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic...Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic...

Antineoplastic Agents, Alkylating Antineoplastic Agents, Regional Perfusion Cancer Chemotherapy, Fungal Proteins, ... Purpose: Isolated, hyperthermic limb perfusion (ILP) with recombinant human tumor necrosis factor alpha and melphalan is a ... and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients ... and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. ...
more infohttp://edoc.mdc-berlin.de/2593/
  • A pathologist views the tissue under a microscope to look for cancer cells and to find out the grade of the tumor. (peacehealth.org)
  • The grade of a tumor depends on how abnormal the cancer cells look under a microscope and how quickly the cells are dividing. (peacehealth.org)
  • The most common types of primary liver cancer are hepatocellular carcinoma (also known as hepatoma) and cholangiocarcinoma. (nice.org.uk)
  • The investigators will analyze and evaluate the effect and safety of an implanted percutaneous left subclavian artery port-catheter drug delivery system for regional chemotherapy of inoperable pancreatic carcinoma. (clinicaltrials.gov)
  • Eggermont AM. TNF alpha in isolated perfusion systems: success in the limb, developments for the liver credits, debits and future perspectives. (springer.com)
  • Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. (springer.com)
  • In patients with primary liver cancer, surgical removal with curative intent may be possible. (nice.org.uk)
  • Gemcitabine has been used as the first-line drug for advance pancreatic cancer for over two decades and combinations of gemcitabine with different chemotherapeutic drugs have been investigated to improve the outcomes of pancreatic cancer. (clinicaltrials.gov)
  • PURPOSE: Preoperative therapy in borderline resectable pancreatic cancer (BRPC) is intended to increase R0 resection rates. (bvsalud.org)
  • Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. (yale.edu)
  • MD Anderson Cancer Center developed a computed tomography (CT)-based preoperative assessment tool simplified preoperative assessment for appendix tumor (SPAAT) for predicting incomplete cytoreduction (IC) in low-grade mucinous adenocarcinoma (LGMA) of the appendix, based on preoperative CT scans. (nih.gov)
  • Usually, the goal is to weaken cancer cells so that they are more likely to be killed by radiation and chemotherapeutic medications. (wikipedia.org)
  • Minimally invasive gastrectomy (MIS) rates are increasing, though the impact of MIS on postoperative chemotherapy remains uncertain. (bvsalud.org)
  • This study examines the outcomes of urgent versus elective surgery for gastric cancer. (bvsalud.org)
  • In 2002, Mr Hayes was awarded a Hunterian Professorship by the Royal College of Surgeons in England for his research into angiogenesis as a therapeutic approach for cancer. (icr.ac.uk)
  • However, cancer occurs more often as a result of metastases from other sites such as the lung, colon, stomach and eye (particularly ocular melanoma). (nice.org.uk)
  • Get the latest cancer research news. (cancervic.org.au)
  • This paper is a Focussed Research Review based on a presentation given at the Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, held in Siena, Italy, 17th- 19th October 2013. (springer.com)
  • Mr Hayes spent three years of research training at the Lombardi Cancer Center, Georgetown University Hospital, Washington DC, US, for which he was awarded a PhD in 2001. (icr.ac.uk)
  • Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research 2014, 20:6406-17. (yale.edu)